BioSpace News Archive

Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Dermata Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer.

MediciNova, Inc. announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD” has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases to be held November 12 - 15, 2021.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of COVID-19 infection.

Lumenis announced the completion of the sale of its Surgical business to Boston Scientific Corporation, a leading global medical device manufacturer, in a transaction valued at $1.07B.

Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of John Strafford, Ph.D., to the newly created role of Senior Vice President, Business Development, Alliance Management and New Product Development, effective immediately.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences:

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in two upcoming virtual investor conferences during the month of September.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 32,130 ordinary shares of Nabriva Therapeutics as an inducement to three newly-hired employees.